Welcome to our dedicated page for COMPASS Pathways plc SEC filings (Ticker: CMPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
COMPASS Pathways plc filings document the regulatory record for a biotechnology company developing COMP360, a proprietary synthetic psilocybin formulation for mental health indications including treatment-resistant depression. Current reports disclose financial results, clinical and regulatory updates, investor presentation materials, and material agreements tied to debt facilities and securities offerings.
Proxy and other filings cover annual general meeting matters, board structure, committee assignments, compensation arrangements, and shareholder voting procedures. Capital-structure disclosures include American Depositary Shares, ordinary shares, pre-funded warrants, registration statement references, underwriting terms, and loan and security agreement amendments.
COMPASS Pathways plc director Jeffrey M. Jonas received a grant of share options linked to 21,110 Ordinary Shares. The options carry an exercise price of $11.85 per share and expire in 2036. They vest in full on the earlier of one year from grant or the company’s 2027 annual shareholder meeting.
COMPASS Pathways plc director Wayne Joseph Riley received a grant of share options covering 21,110 Ordinary Shares. These options were awarded at an exercise price of $11.85 per share and are held directly. Following the grant, his option holdings reported in this filing total 21,110 shares.
The option vests in full on the earlier of the first anniversary of the grant date or the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027, and expires on May 26, 2036. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
COMPASS Pathways plc director Robert McQuade received a grant of share options covering 21,110 Ordinary Shares. These options have an exercise price of $11.85 per share and expire on May 26, 2036. Following this award, he holds options for 21,110 shares directly.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s Annual General Meeting of Shareholders in 2027. The underlying Ordinary Shares may be represented by American Depositary Shares, with each ADS currently representing one Ordinary Share.
COMPASS Pathways plc director David Y. Norton received a grant of share options giving him the right to buy 21,110 Ordinary Shares. The options have an exercise price of $11.85 per share and expire on 26 May 2036. The underlying shares vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual General Meeting of Shareholders. The Ordinary Shares may be represented by American Depositary Shares on a 1:1 basis.
COMPASS Pathways plc director Kathleen Tregoning received a grant of share options covering 41,119 Ordinary Shares. The options have an exercise price of 11.85 per share and expire on May 26, 2036.
The award vests in 36 equal monthly installments over three years, with the first tranche vesting and becoming exercisable on June 27, 2026. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
COMPASS Pathways plc director Kathleen Tregoning has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing reports no transactions in COMPASS Pathways securities, and no derivative positions or other holdings are listed in the provided data.
Compass Pathways plc reported the results of its 2026 Annual General Meeting held on May 27, 2026. Shareholders representing 58,880,058 ordinary shares were present in person or by proxy. The company did not exercise discretionary voting power over American Depositary Shares lacking voting instructions, which were counted as broker non-votes.
Shareholders re-elected Justin Gover, Daphne Karydas and Jeffrey Jonas as directors and elected Kathleen Tregoning to the board. They also re-appointed PwC UK as U.K. statutory auditors, ratified PwC US as independent registered public accounting firm for 2026 and authorized the Audit and Risk Committee to determine auditors’ remuneration.
Investors approved the receipt of the U.K. statutory annual accounts for the year ended December 31, 2025 and noted that no dividend is recommended for that year. They also approved, on a non-binding, advisory basis, the directors’ remuneration report and the compensation of named executive officers. Following the meeting, Annalisa Jenkins’ eight-year term on the board concluded.
COMPASS Pathways plc reporting persons RTW Investments, LP and Roderick Wong, M.D. report beneficial ownership of 12,971,571 shares, representing 9.9% of the class, assuming exercise of 2,339,181 warrants. The percentage is calculated using 128,923,295 shares outstanding as of March 17, 2026.
The filing states the reported shares are held by the RTW Funds and that the RTW Funds have the right to receive dividends or sale proceeds. Shared voting and dispositive power for the reported shares is listed as 12,971,571 for both Reporting Persons.
Compass Pathways reported a strong start to 2026, combining major regulatory progress for its COMP360 psilocybin treatment in treatment-resistant depression with a sharp improvement in reported results. The FDA granted a rolling New Drug Application submission and review, which is already underway, and a Commissioner’s National Priority Voucher that may shorten review timelines.
Part B 26-week data from the COMP006 Phase 3 trial are expected in early Q3 2026, with final NDA submission still targeted for Q4 and launch readiness by year-end. Cash and cash equivalents rose to $466.0 million as of March 31, 2026, supporting a runway into 2028. For the quarter, research and development expenses were $26.5 million and general and administrative expenses were $16.4 million, while a non-cash $130.9 million warrant fair value gain drove net income of $91.2 million versus a prior-year net loss.
Compass Pathways plc reports strong Q1 2026 results, with net income of $91.2 million, driven primarily by a $130.9 million non-cash gain from the fair value change of warrant liabilities. Core operations still produced a loss from operations of $42.9 million as the company continues investing in late-stage development.
Cash and cash equivalents rose to $466.0 million, supported by warrant exercises, a February 2026 underwritten ADS offering, and a new Hercules loan tranche, lifting total assets to $531.7 million. Management believes this cash should fund operating expenses and capital needs into 2028.
Clinically, Compass advanced its COMP360 psilocybin program in treatment-resistant depression, with both pivotal Phase 3 trials (COMP005 and COMP006) meeting primary endpoints and the FDA granting rolling review and a Commissioner’s National Priority Voucher. The company is also initiating a Phase 2b/3 COMP360 trial in PTSD while maintaining a substantial accumulated deficit of $731.4 million.